Hi Biotwitter! I am helping an exciting private biotech to raise money and am looking for angel investors. The company is 18 months away from an IND, has a proven management team and has 10x upside in 18-24 months. If anyone is interested , please DM me asap.
@MattyKirsh As you can see from my many posts on $EDSA, I follow it closely. The problem is that at present, it appears to be ONLY a COVID-associated ARDS story. If it succeeds in an ongoing pure ARDS story, it is another 10-20X
$IOVA Turnaround underway. Replimune sidelined; sarcoma data; now emdometrial ca data (though n=5)
Need to replace hyperbolic CEO, but otherwise this is going higher
$edsa Looks like a great short now on the need for a financing. I still cant entirely explain why the company canceleld their Bloom Burton conference meeting at the last moment. Would NOT short though as one might get caught in an ongoing squeeze
$edsa Sold my entire position in EDSA after a 1500% 2 month return (bought at $1.22 and sold all > $17)
Story is over---the ARDS story is likely entirely COVID ARDS and noone will care about the data due to be presented next week. Vitilgo drug interesting, but company needs $
$CLNN Adam F (whom I greatly respect) bashed CLNN this morning. I disagree with him here as I am a big believer on the importance of Neurofilament light chains. While I agree the difference from placebo for CLNN's "drug" is not as strong as the Nfl data for Qalsody, (cont'd)
$edsa-was supposed to present at the Bloom Burton conference today but canceled. Could be an imminent financing , the CEO is ill (but then why couldn't someone else step in?), or there's another development thats imminent. Could be great news or bad(FDA issue ?)
@adamfeuerstein Love it, but technically, since you as a journalist have pre-release access to key news, isnt that material info on LABU and LABD. for example?
$EDSA--finally, there are many drugs available for vitiligo, but CXCL10, Edesa's EB06 antibody target, has highly compelling preclinical data as the key pathogenetic mechanism. I repeat and again caution that company desperately needs $ but this is a remarkably undervalued story
$edsa--also dont know if anyone noticed, but a filing shows that Perceptive Biosciences bought EDSA--The fund manager is arguably the best in biotech land, except perhaps the Baker brothers---If Perceptive made the effort to buy a tiny stock like this, that is quite remarkable!
$EDSA---I was called late yesterday by Schwab to see if they could use my shares to borrow for short sellers---Of course, I declined but this call suggests that this is a highly difficult stock to short---"no borrow"--stock could soar again if momentum carries it
$EDSA-Mgmt also "postponed" a call on Thursday with a great friend of mine who is a top Street analyst. They are either very shady or a deal is in the works. Could be a dilutive financing or could be a great licensing deal. Who knows?